1. Home
  2. DYN vs SMR Comparison

DYN vs SMR Comparison

Compare DYN & SMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYN
  • SMR
  • Stock Information
  • Founded
  • DYN 1984
  • SMR 2007
  • Country
  • DYN United States
  • SMR United States
  • Employees
  • DYN N/A
  • SMR N/A
  • Industry
  • DYN Medicinal Chemicals and Botanical Products
  • SMR Electrical Products
  • Sector
  • DYN Health Care
  • SMR Industrials
  • Exchange
  • DYN Nasdaq
  • SMR Nasdaq
  • Market Cap
  • DYN 2.6B
  • SMR 2.4B
  • IPO Year
  • DYN 2020
  • SMR N/A
  • Fundamental
  • Price
  • DYN $14.13
  • SMR $21.96
  • Analyst Decision
  • DYN Strong Buy
  • SMR Buy
  • Analyst Count
  • DYN 10
  • SMR 5
  • Target Price
  • DYN $50.70
  • SMR $11.50
  • AVG Volume (30 Days)
  • DYN 1.8M
  • SMR 8.8M
  • Earning Date
  • DYN 03-04-2025
  • SMR 03-13-2025
  • Dividend Yield
  • DYN N/A
  • SMR N/A
  • EPS Growth
  • DYN N/A
  • SMR N/A
  • EPS
  • DYN N/A
  • SMR N/A
  • Revenue
  • DYN N/A
  • SMR $7,381,000.00
  • Revenue This Year
  • DYN N/A
  • SMR N/A
  • Revenue Next Year
  • DYN N/A
  • SMR $278.07
  • P/E Ratio
  • DYN N/A
  • SMR N/A
  • Revenue Growth
  • DYN N/A
  • SMR N/A
  • 52 Week Low
  • DYN $14.03
  • SMR $1.92
  • 52 Week High
  • DYN $47.45
  • SMR $32.30
  • Technical
  • Relative Strength Index (RSI)
  • DYN 19.54
  • SMR 53.19
  • Support Level
  • DYN $14.79
  • SMR $18.13
  • Resistance Level
  • DYN $15.90
  • SMR $24.10
  • Average True Range (ATR)
  • DYN 1.55
  • SMR 2.05
  • MACD
  • DYN -0.82
  • SMR 0.24
  • Stochastic Oscillator
  • DYN 0.82
  • SMR 68.90

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

About SMR NuScale Power Corporation

NuScale Power Corp is engaged in the development of a new modular light water reactor nuclear power plant to supply energy for electrical generation, district heating, desalination, hydrogen production, and other process heat applications.

Share on Social Networks: